In this study looked for PLK1-combination targets in non-small cell lung cancer cells (NSCLC), a clinically important tumor type that is driven to a significant degree by mutations in TP53 and KRAS and that as a whole are particularly sensitive to PLK1 inhibition [7]. The gene discussed is PLK1; the disease is non-small cell lung carcinoma.